Polskie Radio covers the approval status of Eli Lilly's experimental weight loss drug retatrutide. Details are thin, so tap through for the full picture.
Recap by typeshit. Full story at www.polskieradio.pl.
A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
A video walks through retatrutide and how targeting GIP and glucagon alongside GLP-1 sets it apart from current drugs.
A short rundown of how retatrutide is built to act on GLP-1, GIP and glucagon receptors, and what those pathways may affect, like appetite and blood sugar.
Loading…